NCT02062502已完成3 期
A Phase III Double Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX™ New Seed Process (NSP) Administered Concomitantly With M-M-R™ II
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 611
- 主要终点
- Percentage of Participants With Varicella Zoster Virus (VZV) Antibody Levels >=5 Glycoprotein Enzyme-linked Immunosorbent Assay (gpELISA) Units/mL
研究概览
简要总结
This study will evaluate the immunogenicity, safety, and tolerability of VARIVAX™ (Varicella Virus Vaccine Live) manufactured with a New Seed Process (NSP) compared with the VARIVAX™ 2007 process. The primary hypotheses being tested are that antibody response rate and mean antibody titer induced at 6 weeks after a single vaccination by VARIVAX™ NSP are non-inferior to those induced by VARIVAX™ 2007 process, and that antibody response rate induced by VARIVAX™ NSP is acceptable.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 12 Months 至 23 Months（Child）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Negative clinical history for varicella, herpes zoster, measles, mumps, and rubella
排除标准
- •Received any measles, mumps, rubella, or varicella vaccine at any time prior to the study, or is anticipated to receive any of these vaccines outside the study
- •Any congenital or acquired immune deficiency, neoplastic disease, or depressed immunity
- •Received systemic immunomodulatory steroids within 3 months prior to entering the study or is expected to receive them during the course of the study
- •History of allergy or anaphylactic reaction to neomycin, gelatin, sorbitol, egg proteins, chicken proteins, or any component of VARIVAX™ or M-M-R II™
- •Received salicylates within 14 days prior to study vaccination
- •Exposed to varicella, herpes zoster, measles, mumps, or rubella in the 4 weeks prior to study vaccination
- •Received immune globulin, a blood transfusion, or blood-derived products within 5 months prior to study vaccination
- •History of seizure disorder, including febrile seizure
- •Fever illness (>=102.2 °F [39.0 °C] within 72 hours prior to study vaccination
- •History of thrombocytopenia
- •Born to a human immunodeficiency virus (HIV)-infected mother
- •Participated in any other clinical trial (other than a surveillance study) within 30 days prior to study enrollment.
结局指标
主要结局
Percentage of Participants With Varicella Zoster Virus (VZV) Antibody Levels >=5 Glycoprotein Enzyme-linked Immunosorbent Assay (gpELISA) Units/mL
时间窗: 6 weeks (43 days) after vaccination 1
Geometric Mean Titer of VZV Antibodies
时间窗: 6 weeks (43 days) after vaccination 1
Antibody titers were measured with gpELISA.
次要结局
- Percentage of Participants With Solicited Injection-site Erythema, Injection-site Swelling, and Injection-site Pain/Tenderness After Vaccination 1(Up to 5 days after Vaccination 1)
- Percentage of Participants With Solicited Injection-site Erythema, Injection-site Swelling, and Injection-site Pain/Tenderness After Vaccination 2(Up to 5 days after Vaccination 2)
- Percentage of Participants With Fever (>=102.2 °F Oral Equivalent)(Up to 42 days after Vaccination 1 and Vaccination 2 (up to 133 days))
- Percentage of Participants With Systemic Measles-like, Rubella-like, Varicella-like Rash, Mumps-like Symptoms, and Injection-site Rash After Vaccination 2(Up to 42 days after Vaccination 2)
- Percentage of Participants With Systemic Measles-like, Rubella-like, Varicella-like Rash, Mumps-like Symptoms, and Injection-site Rash After Vaccination 1(Up to 42 days after Vaccination 1)
研究者
相似试验
已完成
3 期
Evaluation of Immunogenicity and Safety of VARIVAX® Passage Extension 34 (PE34) Process in Children (V210-A03)VaricellaNCT03239873Merck Sharp & Dohme LLC600
撤回
3 期
A Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX™ Manufactured With a New Process (V210-062)VaricellaNCT01626794Merck Sharp & Dohme LLC
已完成
3 期
Immunogenicity and Safety of Varicella Vaccine, Live in Healthy Children Aged 12~15 Months in the PhilippinesVaricellaNCT06314724Sinovac (Dalian) Vaccine Technology Co., Ltd.642
已完成
2 期
Immunogenicity and Safety of GSK Biologicals' Live Attenuated Varicella Vaccine (VARILRIXTM).VaricellaNCT00792623GlaxoSmithKline45
已完成
3 期
Study to Test the Safety and Immunogenicity of VARIVAX (2007 Process) (Study V210-057) (Completed)VaricellaNCT00822237Merck Sharp & Dohme LLC598